Abstract Number: 384 • 2017 ACR/ARHP Annual Meeting
Protection Against Hepatitis B in Immunocompromised Pediatric Rheumatology and Gastroenterology Patients
Background/Purpose: Hepatitis B infection remains a significant public health challenge, particularly for patients on chronic immunosuppressive therapy, due to a considerable mortality risk associated with…Abstract Number: 385 • 2017 ACR/ARHP Annual Meeting
Reliable Implementation of a Hepatitis B Serology Screening and Vaccination Process for Immunocompromised Pediatric Rheumatology Patients
Background/Purpose: Vaccine-preventable infections, including reactivation of hepatitis B virus, are a leading cause of morbidity and mortality in immunocompromised patients. Guidelines recommend that all immunosuppressed…Abstract Number: 1277 • 2017 ACR/ARHP Annual Meeting
Longitudinal Predictors of Physical Function in Juvenile Myositis
Background/Purpose: Juvenile myositis (JM) is marked by skin rashes, proximal muscle weakness, and deconditioning causing potentially severe disability. Studies examining long-term physical function in JM…Abstract Number: 1284 • 2017 ACR/ARHP Annual Meeting
The Localized Scleroderma Quality of Life Instrument (LoSQI): Initial Validation in Pediatric Localized Scleroderma
Background/Purpose: There is a current need to integrate health related quality of life (HRQoL) into outcomes for clinical trials (Chang & Reeve, 2005). For pediatric…Abstract Number: 1285 • 2017 ACR/ARHP Annual Meeting
Extracutaneous Involvement Is Common in Juvenile Localized Scleroderma and Associated with a Higher Level of Perceived Disease Impact
Background/Purpose: Juvenile localized scleroderma (jLS) is often associated with deep tissue and extracutaneous involvement (ECI), putting children at risk for severe morbidity such as hemiatrophy,…Abstract Number: 1288 • 2017 ACR/ARHP Annual Meeting
Renal Disease Course in Pediatric Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis in the First 12-Months – a Pediatric Vasculitis Initiative (PedVas) Study
Background/Purpose: Renal disease is the most common manifestation of pediatric anti-neutrophil cycloplasmic antibody (ANCA) associated vasculitis (AAV). Renal disease course and early trajectories have not…Abstract Number: 1728 • 2017 ACR/ARHP Annual Meeting
Interferon Gamma (IFN-γ) Subpopulations in Skin Homing T Cells of Localized Scleroderma
Background/Purpose: Localized scleroderma (LS) has both inflammatory and fibrotic components contributing to its effect on the skin and underlying tissue. The understanding of the pathophysiology…Abstract Number: 2252 • 2017 ACR/ARHP Annual Meeting
Initial Validation of Patient-Reported Outcomes Measurement Information System (PROMIS®) in Children with Juvenile Myositis
Background/Purpose: Juvenile myositis (JM) can worsen quality of life (QoL) via proximal weakness, rashes, and treatments side effects. QoL legacy instruments may be limited by…Abstract Number: 64 • 2017 Pediatric Rheumatology Symposium
Evaluating Levels of Activity and Health-Related Quality of Life in a Pilot Cohort of Youth Athletes with Juvenile Idiopathic Arthritis
Background/Purpose: Children with JIA are increasingly being encouraged to be physically active and are participating in organized and competitive sports as youth athletes. These youth…Abstract Number: 47 • 2017 Pediatric Rheumatology Symposium
Baseline characteristics of the first 123 patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA comparative effectiveness study
Background/Purpose: Many new effective treatments for polyarticular JIA (p-JIA) are available, but there is significant variation among pediatric rheumatologists in the timing of when biologic…Abstract Number: 60 • 2017 Pediatric Rheumatology Symposium
Paediatric Arthritis Rehabilitation Exercise Study
JIA patients often require regular exercises to increase joint range of motion (ROM). Adherence is challenging; instruction by a physiotherapist (PT) / occupational therapist (OT)…Abstract Number: 1810 • 2016 ACR/ARHP Annual Meeting
Health Care Utilization Preceding Diagnosis of Systemic Lupus Erythematosus in Youth
Background/Purpose: Early diagnosis and treatment of youth with SLE are crucial to prevent organ damage and reduce mortality. Understanding health care utilization prior to diagnosis…Abstract Number: 1971 • 2016 ACR/ARHP Annual Meeting
Predictors of Delays to Care and Associated Outcomes in Pediatric Lupus Patients from the Childhood Arthritis and Rheumatology Research Alliance Registry
Background/Purpose: CARRA registry data for participants meeting ACR classification criteria for lupus were analyzed. Delays of one month, 3 months, and one year from symptom…Abstract Number: 2038 • 2016 ACR/ARHP Annual Meeting
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Improvement on Quality Measures for Children with Juvenile Idiopathic Arthritis
Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a growing multi-center network organized on a learning health system model designed to improve outcomes…Abstract Number: 2392 • 2016 ACR/ARHP Annual Meeting
Establishing Quality of Life Content Domains in Pediatric Localized Scleroderma
Background/Purpose: Localized scleroderma (LS) can affect patients' physical function and psychosocial well-being, but, published studies of the impact of pediatric LS on health-related quality of…
- « Previous Page
- 1
- …
- 46
- 47
- 48
- 49
- 50
- …
- 52
- Next Page »